In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: MetLife’s current price ($87.58) is significantly below its PERT-weighted fair value ($145.05), indicating substantial upside potential. However, earnings multiple methods show mixed confidence and moderate valuation dispersion, while Monte Carlo simulations reveal high volatility and a 22.2% chance of downside below the current price. Financial health is fair but efficiency is low, reflecting risk amid growth prospects.